Effects of arginine vasopressin deficiency on cardiac fibrosis in male Wistar rats
Physiological Reports · 2026-01 · 14 (2)
DOI: 10.14814/phy2.70748 ↗Kurz gefasst
Fachartikel in der Zeitschrift Physiological Reports, online erschienen am 28.01.2026. Verfasst von A Limón-Mendoza und 7 weiteren Autor:innen. Beteiligte Einrichtung: Laboratorio de Neuroinmunoendocrinología. Departamento de Fisiología y Farmacología. Centro de Ciencias Básicas, Universidad Autónoma de Aguascalient…. Hauptthemen laut MEDLINE: Arginine Vasopressin, Myocardium. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 29 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Autonomous University of Aguacalientes.
Abstract (Originalsprache)
Cardiac fibrosis represents a consequence of hypertensive heart disease and is associated with ventricular dysfunction, arrhythmias, and mortality. Arginine vasopressin (AVP) promotes myofibroblast proliferation and collagen synthesis through V1a receptors. While hepatic studies suggest that AVP deficiency attenuates fibrosis, its cardiac impact remains unclear. This study evaluated the effects of AVP deficiency induced by neurointermediate pituitary lobectomy (NIL) and pharmacological V1a/V2 blockade with conivaptan (CV) in rats with fibrosis from abdominal aortic stenosis (AAC). Wistar rats were divided into seven groups with 10 animals each. Clinical variables and histopathology (H&E, Masson's trichrome, picrosirius red) were assessed. ANOVA, Fisher and Mantel‐Cox tests were applied. The Fibrosis (F) group developed hypertrophy, hypertension, higher arrhythmia risk and increased fibrosis. In contrast, F+NIL and F+CV showed blood pressure and cardiac morphology comparable to controls, reduced arrhythmia risk and significantly less fibrosis. Histologically, F+NIL achieved partial regression, whereas F+CV nearly normalized tissue architecture. In conclusion, AVP deficiency or receptor blockade decreases and reverses AAC‐induced fibrosis, improving hemodynamic, electrical, and structural outcomes. V1a/V2 blockade emerges as a potential therapeutic strategy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Laboratorio de Neuroinmunoendocrinología. Departamento de Fisiología y Farmacología. Centro de Ciencias Básicas, Universidad Autónoma de Aguascalientes, Aguascalientes, México.
ORCID-Profile: A Limón-Mendoza, A Quintanar-Stephano
Förderung
- Autonomous University of Aguacalientes
Zitieren
APA
Limón-Mendoza, A., Alamilla-Rasso, J., González-Nuñez, S., Becerra-Mendez, M., García-Álvarez, S., Tinajero-Vidales, K., Tinajero-Ruelas, M., & Quintanar-Stephano, A. (2026). Effects of arginine vasopressin deficiency on cardiac fibrosis in male Wistar rats. Physiological Reports, 14(2). https://doi.org/10.14814/phy2.70748
Vancouver
Limón-Mendoza A, Alamilla-Rasso J, González-Nuñez S, Becerra-Mendez M, García-Álvarez S, Tinajero-Vidales K, et al. Effects of arginine vasopressin deficiency on cardiac fibrosis in male Wistar rats. Physiological Reports. 2026;14(2). doi:10.14814/phy2.70748
BibTeX
@article{LimnMendoza2026,
author = {Limón-Mendoza, A and Alamilla-Rasso, J and González-Nuñez, S and Becerra-Mendez, M and García-Álvarez, S and Tinajero-Vidales, K and Tinajero-Ruelas, M and Quintanar-Stephano, A},
title = {Effects of arginine vasopressin deficiency on cardiac fibrosis in male Wistar rats},
journal = {Physiological Reports},
year = {2026},
volume = {14},
number = {2},
doi = {10.14814/phy2.70748}
}
EUVIMED